Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats

Pain

Volumn 105, Issue 1-2, 2003, Pages 275-283

  Lim, Grewo ^a   Sung, Backil ^a   Ji, Ru Rong ^b   Mao, Jianren ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Allodynia; Cannabinoid receptor; Hyperalgesia; Mitogen activated protein kinase; Nerve injury; Neuropathic pain; Tyrosine kinase; Win 55,212 2

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CHELERYTHRINE; K 252A; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR;

ALLODYNIA; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; MALE; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NERVE INJURY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; REDUCTION; SPINAL CORD DORSAL HORN; UPREGULATION; WESTERN BLOTTING;

EID: 0141738711     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(03)00242-2     Document Type: Article

References (92)

1. 2+-responsible secretory vesicles through the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. J Biochem (Tokyo). 131:2002;887-894.
2. Arner S., Meyerson B.A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 33:1988;11-23.
3. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 33:1988;87-107.
4. Bridges D., Ahmed K., Rice A.S. The synthetic cannabinoids WIN 55,2122 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 133:2001;586-594.
5. Childers S.R., Breivogel C.S. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend. 51:1998;173-187.
6. 9-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther. 297:2001;121-127.
7. Coffey E.T., Akerman K.E.O., Courtney M.J. Brain derived neurotrophic factor induces a rapid upregulation of synaptophysin and tau protein via the neurotrophin receptor TrkB in rat cerebellar granule cells. Neurosci Lett. 227:1997;177-180.
8. Cosenza M., Gifford A.N., Gatley S.J., Pyatt B., Liu Q., Makriyannis A., Volkow N.D. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse. 15:2000;477-482.
9. Davar G., Maciewicz R.J. Deafferentation pain syndromes. Neurol Clin. 7:1989;289-304.
10. Deng Y.S., Zhong J.H., Zhou X.F. Effects of endogenous neurotrophins on sympathetic sprouting in the dorsal root ganglia and allodynia following spinal nerve injury. Exp Neurol. 164:2000;344-350.
11. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in the rat brain. Mol Pharmacol. 34:1988;605-613.
12. Do S.H., Fang H.Y., Ham B.M., Zou Z. The effects of lidocaine on the activity of glutamate transporter EAAT3: the role of protein kinase C and phosphatidylinositol kinase. Anesth Analg. 95:2002;1263-1268.
13. Dove Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., Cabral G.A. Immunohistochemical localization of the neuronal cannabinoid receptors in rat brain. J Neurosci Res. 51:1998;391-402.
14. Dubner R. A call for more science, not rhetoric, regarding opioids and neuropathic pain. Pain. 47:1991;1-2.
15. Dubner R. Neuronal plasticity and pain following peripheral tissue inflammation or nerve injury. Bond M., Charlton E., Woolf C.J. Pain research and clinical management. Pain research and clinical management. vol. 5:1991;263-276 Elsevier, Amsterdam.
16. Dubner R., Hargreaves K.M. The neurobiology of pain and its modulation. Clin J Pain Suppl. 2:1989;S1-S4.
17. Encinas M., Iglesias M., Llecha N., Comella J.X. Extracellular-regulated kinases and phosphatidylinositol 3kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SHSY5Y. J Neurochem. 73:1999;1409-1421.
18. Farquhar-Smith W.P., Egertova M., Bradbury E.J., McMahon S.B., Rice S.A., Elphick M.R. Cannabinoid CB(1) receptor expression in the rat spinal cord. Mol Cell Neurosci. 15:2000;510-521.
19. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
20. Fuentes J.A., Ruiz-Gayo M., Manzanares J., Vela G., Reche I., Corchero J. Cannabinoids as potential new analgesics. Life Sci. 65:1999;675-685.
21. Gardell L.R., Ossipov M.H., Vanderah T.W., Lai J., Porreca F. Dynorphin-independent spinal cannabinoid antinociception. Pain. 100:2002;243-248.
22. Gonzalez-Rosales F., Walsh D. Nausea and vomiting due to gastrointestinal mucous metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manage. 14:1997;311-314.
23. Guhring H., Schuster J., Hamza M., Ates M., Kotalla C.E., Brune K. HU210 shows higher efficacy and potency than morphine after intrathecal administration in the formalin test. Eur J Pharmacol. 429:2001;127-134.
24. Ha S.O., Kim J.K., Hong H.S., Kim D.S., Cho H.J. Expression of brain-derived neurotrophin factor in rat dorsal root ganglioma, spinal cord and gracile nuclei in experimental models of neuropathic pain. Neuroscience. 107:2001;301-309.
25. Hagemann C., Blank J.L. The ups and downs of MEK kinase interactions. Cell Signal. 13:2001;863-875.
26. Hamann W., di Vadi P.P. Analgesic effects of the cannabinoid analogue nabilone is not mediated by opioid receptor. Lancet. 353:1999;560.
27. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32:1988;77-88.
28. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and location of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 11:1991;563-583.
29. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effect of R(+)Win 55,2122 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 221:1997;157-160.
30. Holdcroft A., Smith M., Jacklin A., Hodgson H., Smith B., Newton M., Evans F. Pain relief with oral cannabinoids in familial Mediterranean fever. Anesthesia. 52:1997;483-486.
31. Jadad A.R., Carroll D., Glynn C.J., Moore R.A., McQuay H.J. Morphine responsiveness of chronic pain: double-blind randomized crossover study with patient-controlled analgesia. Lancet. 339:1992;1367-1371.
32. Jansen E.M., Haycock D.A., Ward S.J., Seybold V.S. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 575:1992;93-102.
33. Ji R.R., Befort K., Brenner G.J., Woolf C.J., ERK M.A.P. kinase activation in superficial spinal cord neurons induces prodynorphin and NK1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci. 22:2002;478-485.
34. Kingery W.S. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 73:1997;123-139.
35. Kishore-Kumar R., Max M.B., Schafer S.C., Gaughan A.M., Smoller B., Gracely R.H., Dubner R. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 47:1990;305-312.
36. Kumar R.N., Chambers W.A., Pertwee R.G. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anesthesia. 56:2001;1059-1068.
37. Kupers R.C., Konings H., Adriaensen H., Gybels J.M. Morphine differentially affects the sensory and affective pain rating in neurogenic pain and idiopathic forms of pain. Pain. 47:1991;5-12.
38. Li W.P., Xian C., Rush R.A., Zhou X.F. Upregulation of brain-derived neurotrophic factor and neuropeptide Y in the dorsal ascending sensory pathway following sciatic nerve injury in rat. Neurosci Lett. 260:1999;49-52.
39. Lichtman A.H., Martin B.R. Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J Pharmacol Exp Ther. 258:1991;517-523.
40. Malan T.P., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
41. Mannion R.J., Costigan M., Decosterd I., Ma Q.P., Holstege J.C., Ji R.R., Acheson A., Lindsay R.M., Reichard L., Woolf C.J. Brain-derived neurotrophic factor - a centrally activating modulator of stimulus-induced pain hypersensitivity. Proc Natl Acad Sci USA. 96:1999;9385-9390.
42. Mao J., Chen L.L. Gabapentin in pain management. Anesth Analg. 91:2000;680-687.
43. Mao J., Chen L.L. Systemic lidocaine for neuropathic pain relief. Pain. 87:2000;7-17.
44. Mao J., Price D.D., Mayer D.J. Mechanisms of hyperalgesia and opiate tolerance: a current view of their possible interactions. Pain. 62:1995;259-274.
45. Mao J., Price D.D., Mayer D.J. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain. 61:1995;353-364.
46. Mao J., Price D.D., Zhu J., Lu J., Mayer D.J. The inhibition of nitric oxide-activated poly(ADPribose) synthetase attenuates transsynaptic alteration of spinal cord dorsal horn neurons and neuropathic pain in the rat. Pain. 72:1997;355-366.
47. Mao J., Price D.D., Lu J., Keniston L., Mayer D.J. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett. 280:2000;13-16.
48. Mao J., Sung B., Ji R.R., Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 22:2002;8312-8323.
49. Martin B.R., Lichtman A.H. Cannabinoid transmission and pain perception. Neurobiol Dis. 5:1998;447-461.
50. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.L., Bonnner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
51. Max M.B. Treatment of postherpetic neuralgia: antidepressants. Ann Neurol. 35:1994;S50-S53.
52. Max B., Kishore-Kumar R., Schafer S.C., Merster B., Gracely R.H., Smoller B., Dubner R. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 45:1991;3-9.
53. Max B., Lynch S.A., Muir J., Shoaf S.E., Smoller B., Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 326:1992;1250-1256.
54. Meller S.T., Dykstra C., Gebhart G.F. Acute thermal hyperalgesia in the rat is produced by activation of N-methyl-D-aspartate receptors and protein kinase C and production of nitric oxide. Neuroscience. 71:1996;327-335.
55. Munro S., Thomas K.L., AbuShaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
56. Ossipov M.H., Lopez Y., Nichols M.L., Bian D., Porreca F. The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci Lett. 199:1995;87-90.
57. Oyesiku N.M., Evans C.O., Houston S., Darrell R.S., Smith J.S., Fulop Z.L., Dixon C.E., Stein D.G. Regional changes in the expression of neurotrophic factors and their receptors following acute traumatic brain injury in the adult rat brain. Brain Res. 833:1999;161-172.
58. Pascual M., Climent E., Guerri C. BDNF induces glutamate release in cerebrocortical nerve terminals and in cortical astrocytes. Neuroreport. 12:2001;2673-2677.
59. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol. 63:2001;569-611.
60. Piomelli D., Giuffrida A.C., Calignano A., de Fonseca F.R. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci. 21:2000;218-224.
61. Portenoy R.K., Foley K.M., Inturrisi C.E. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusion. Pain. 43:1990;273-277.
62. Raja S.N., Haythornthwaite J.A., Pappagallo M., Clark M.R., Travison T., Sabeen S., Royall R.M., Max M.B. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 59:2002;1015-1021.
63. Richardson J.D., Aanonsen L., Hargreaves K.M. SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol. 319:1997;R3-R4.
64. Richardson J.D., Aanonsen L., Hargreaves K.M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci. 18:1998;451-457.
65. Richardson J.D., Aanonsen L., Hargreaves K.M. Antihyperalgesic effect of spinal cannabinoids. Eur J Pharmacol. 345:1998;145-153.
66. Rice A.S. Cannabinoids and pain. Curr Opin Invest Drugs. 2:2001;399314.
67. Rowbotham M.C., Twilling L., Davis P.S., Reisner L., Taylor K., Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 348:2003;1223-1232.
68. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 76:1998;3-8.
69. Salio C., Fischer J., Franzoni M.F., Conrath M. Pre- and postsynaptic localization of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience. 110:2002;755-764.
70. Siegling A., Hofmann K.A., Denzer D., Mauler F., Vry J.D. Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol. 415:2001;R5-R7.
71. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatment of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 83:1999;389-400.
72. Siuciak J.A., Altar C.A., Wiegand S.J., Lindsay R.M. Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3. Brain Res. 633:1994;326-330.
73. Smith P.B., Martin R.B. Spinal mechanisms of delta9 tetrahydrocannabinol-induced analgesia. Brain Res. 578:1992;8-12.
74. Strangman N.M., Patrick S.L., Hohmann A.G., Tsou K., Walker J.M. Evidence for a role of endogenous cannabinoids in the modulation of acute and chronic pain sensitivity. Brain Res. 813:1998;323-328.
75. Tal M., Bennett G.J. Extraterritorial pain in rats with a peripheral mononeuropathy: mechanohyperalgesia and mechanoallodynia in the territory of an uninjured nerve. Pain. 57:1994;275-382.
76. Taylor H.G. Analysis of the medical use of marijuana and its societal implications. J Am Pharm Assoc (Wash). 38:1998;220-227.
77. Theodosiou M., Rush R.A., Zhou X.F., Hu D., Walker J.S., Tracey D.J. Hyperalgesia due to nerve damage: role of nerve growth factor. Pain. 81:1999;245-255.
78. Thomas P.K. Clinical features and differential diagnosis of peripheral neuropathy. Dyck P.J., Thomas P.K., Lambert E.H., Bunge R. Peripheral neuropathy. 1984;1169-1190 Saunders, Philadelphia, PA.
79. Troller U., Zeidman R., Svensson K., Larsson C. A PKCbeta isoform mediates phorbol ester-induced activation of Erk1/2 and expression of neuronal differentiation genes in neuroblastoma cells. FEBS Lett. 508:2001;126-130.
80. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
81. Walker J.M., Hohmann A.G., Martin W.J., Strangman N.M., Huang S.M., Tsou K. The neurobiology of cannabinoid analgesia. Life Science. 65:1999;665-673.
82. Walker S.M., Mitchell V.A., White D.M., Rush R.A., Duggan A.W. Release of immunoreactive brain-derived neurotrophic factor in the spinal cord of the rat following sciatic nerve transection. Brain Res. 899:2001;240-247.
83. Watson C.P.N., Evans R.J. A comparative trial of amitriptyline and zimelidine in postherpetic neuralgia. Pain. 23:1982;387-394.
84. Watson C.P.N., Evans R.J., Reed K., Merskey H., Goldsmith L., Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 32:1982;671-673.
85. Watson S.J., Benson J.A., Joy J.E. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 57:2000;547-552.
86. Wegert S., Ossipov M.H., Nichols M.L., Bian D., Vanderah T.W., Malan T.P. Jr, Porreca F. Differential activities of intrathecal MK801 or morphine to alter responses to thermal and mechanical stimuli in normal and nerve-injured rats. Pain. 71:1997;57-64.
87. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther. 262:1992;10-18.
88. Werner N.A., Koch J.E. Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res. 28:2003;290-292.
89. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 353:1999;1959-1964.
90. Yaksh T.L., Rudy T.A. Chronic catheterization of the spinal subarachnoid space. Physiol Behav. 17:1976;1031-1036.
91. Zeltser R., Seltzer Z., Eisen A., Feigenbaum J.J., Mechoulam R. Suppression of neuropathic pain behavior in rats by a nonpsychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain. 47:1991;95-103.
92. Zhang X., Bao L., Shi T.J., Ju G., Elde R., Hokfelt T. Down-regulation of mu-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy. Neuroscience. 82:1998;223-240.